Purpose Chronic GC administration has numerous side effects, but little is known about the side effects of their short-term use (< 3 months)-particularly, when high doses are involved, as in the treatment of Graves' orbitopathy (GO). We investigated the effects of short-term, high-dose GC on bone turnover markers, bone mineral density (BMD), and trabecular bone scores (TBS). Methods Eleven patients (10 females and 1 male; median age 56 years) with active GO who were candidates for treatment with intravenous (iv) methylprednisone were consecutively enrolled. All patients were pretreated with a loading dose of 300,000 units of cholecalciferol, then given a median cumulative dose of 4.5 g (range 1.5-5.25 g) iv methylprednisone. Biochemical parameters of bone metabolism (25OHD3, PTH, P1NP, CTX and bALP) were measured at the baseline, and then 1 week and 1, 3, 6 and 12 months. BMD and TBS were obtained by X-ray absorptiometry (DXA) at the baseline and at 6 and 12 months. On DXA image, morphometric vertebral fracture assessment (VFA) was done. Results There were no significant changes in PTH, bALP or P1NP. A significant drop in CTX was seen at 1 month (down Δ49.31% from the baseline, p = 0.02), with a return to the baseline at the 3-month measurement. There was a moderate (not significant), but persistent reduction in P1NP. No changes in BMD or TBS came to light. No vertebral fractures were documented. Conclusions Short-term, high-dose GC treatment caused a rapid, transient suppression of bone resorption, with no effects on BMD or bone micro-architecture (TBS).
Introduction
Glucocorticoids (GCs) are widely used in clinical practice, in a variety of schemes and doses, for their anti-inflammatory and immunosuppressant properties. It has been estimated that 0.5-0.9% of the general population are prescribed GCs [1] , but their use is burdened with numerous side effects. Chronic GC administration is a well-known risk factor for bone loss, accounting for the most common form of secondary osteoporosis [2] . The pathogenesis of GCinduced osteoporosis is multifactorial. In chronic GC users, the main direct mechanism of bone loss is a decrease in bone formation due to an impaired osteoblastic pool and differentiation, especially in the early phase [3] . GCs also stimulate osteoclast recruitment and activity, however, leading to an enhancement of bone resorption. They have several indirect effects on the skeleton too, reducing calcium [4] absorption from the gastrointestinal tract and renal tubular calcium reabsorption [2] , and causing muscle weakness, with a consequently higher incidence of falls. They ultimately raise the rate of fractures, which occur in as many as 30-50% of chronic GC users [5] . Bone loss is not linear; it is much more severe in the early months of treatment, then slows with time. Although the mechanisms underlying this shift are not clear, it has been suggested that osteoblastic inhibition eventually leads to a decline in the osteoblast-regulated osteoclastogenic signal [5] .
In such a scenario, researchers and guidelines suggest that men and postmenopausal women chronically taking GCs (prednisone or the like at a dose of 2.5-5 mg/day for more than 3 months) should be considered for treatment with bisphosphonates to prevent bone loss [3, 6] . It is worth noting that GCs affect bone quality rather than total bone mass [3] . BMD is an indicator of mineral content per area, expressed in g/cm 2 when measured using dual energy X-ray absorptiometry (DXA). Bone quality is a matter not just of mineralization, but also of bone micro-architecture, the parameter most affected in chronic GC users. The trabecular bone score (TBS) was introduced in 2008 as a new tool for assessing bone micro-architecture [7] . It is a textural index based on pixel grey level variations identifiable on lumbar spine DXA [8] , and therefore, an indirect indicator of the trabecular micro-architecture.
In short, bone loss in chronic GC users is a well-known issue, but most studies and observations involved patients given long-term treatment with various doses of GCs [5, 6, 9] , while little is known about the effects on bone of shortterm, high-dose GC therapies. In vitro studies show how GCs play a role in the differentiation process of a mesenchymal precursor toward osteoblast rather than adipocyte [10] , with GCs having both catabolic and anabolic effects on bone [11] . Mechanisms of action are still to be completely elucidated, but there seems to be a biphasic, dose-dependent effect of GCs on osteoblast in cell culture. Indeed, low doses promote osteoblast activity [11] , while high doses result in suppression of osteoblast differentiation. Similarly, in vitro, GCs have a stimulatory effect on osteoclasts resorption activity at low doses and suppressive effect at high concentrations. In murine models, osteoclast and osteoblast activity is increased during early treatment, but with prolonged exposition to high GCs levels osteoblast activity is inhibited and osteoclasts do not differentiate [12] . One example in clinical practice of the need for a short period (< 3 months) of high-dose GCs is to manage Graves' orbitopathy (GO). This condition occurs in up to 20% of patients with Graves' hyperthyroidism, a not infrequent disease with an incidence of 42.2 per million population per year [13] . The first-line treatment for moderate-to-severe, active GO involves high doses of intravenous (iv) GCs, for a recommended cumulative dose of 4.5 g (i.e. methylprednisone 0.5 g once a week for 6 weeks, followed by 0.25 g once a week for 6 weeks), to strike the best balance between ophthalmic symptom improvement and frequency of adverse effects. Higher doses are allowable in the worst cases of moderate-to-severe GO [13] . The recommended panel of exams to ascertain patients' eligibility for iv GC administration does not include assessing their bone quality, although bone protection is suggested for patients with multiple risk factors for osteoporosis [13] .
The patients selected for the present study had GO necessitating high doses of iv GC treatment, and no concomitant diseases affecting bone, and their data were prospectively collected. The study aimed to investigate acute and mediumterm effects (up to 12 months) on bone of a brief period (12 weeks) of high-dose iv methylprednisone administration. Longitudinal patterns of serum bone markers, BMD and TBS were examined to assess the effect of this particular GC treatment regimen on bone health.
Subjects and methods

Patients
The study was conducted at the Endocrinology Unit of Padua University and General Hospital (Italy) from July 2014 to January 2017. All procedures were performed in accordance with the Declaration of Helsinki. The present study was notified to our Local Ethical Committee (Azienda Ospedaliera di Padova) and all patients gave their written informed consent before their enrollment. Eleven patients (10 females and 1 male, aged 41-71 years; median age 56 years) with moderate or severe active GO, diagnosed according to the EUGOGO criteria [13] were enrolled consecutively. Their median BMI was 24.5 (range 19.1-37 kg/cm 2 ). All patients were euthyroid when their iv GC treatment was started. Their hyperthyroidism had been brought under control medically with methimazole (7/11 patients), surgically with thyroidectomy (3/11 patients), or with 131 I radioiodine treatment (1/11 patient). The following exclusion criteria were considered: a state of hyper-or hypothyroidism, hypovitaminosis D, a history of acute or chronic diseases affecting bone, treatment with drugs known to influence bone metabolism in the previous 6 months, smoking (more than 10 cigarettes/day), alcohol intake of more than 3 alcohol units/day, pregnancy, menopause within the previous 5 years, and a personal or family history of pathological osteoporotic fractures. Patients' eligibility for iv GC administration was assessed by means of a pretreatment screening at our center, which includes the following tests as part of our routine clinical practice: creatinine and estimated glomerular filtration rate (eGFR), complete blood count, liver enzymes and autoimmunity, glucose, blood pressure, HBV-HCV and HBV antibody, and quantiferon. For the specific purposes of this study, calcium and phosphate (in all participants), and total testosterone (in males) were measured before the treatment. Methylprednisone was administered at the recommended dosage of 0.5 g once a week for 6 weeks, then 0.25 g once a week for another 6 weeks (cumulative dose 4.5 g) in most cases. Lower doses were used for 4 patients, as planned in 2 of them, and due to side effects of GCs in the other 2 (1 patient experienced weight gain, the other insomnia and irritability). A higher dose was used for 1 patient with particularly severe GO. The median methylprednisone dose in our sample was consequently 4.5 g (range 1.5-5.25 g). Six of the 10 women had been postmenopausal from more than 5 years. All patients received a single, high dose of oral cholecalciferol (300,000 IU) a week before the first methylprednisone infusion to ensure their vitamin D (25OHD3) status was adequate. Patients given methylprednisone for GO are routinely tested for blood count, liver enzymes, and blood pressure. The patients in our sample were also given a questionnaire to assess their dietary intake of dairy products (considering an intake of at least 1 portion a day as sufficient).
Biochemical analysis
Samples were collected from patients at the baseline and after 1 week, and then 1, 3, 6 and 12 months after starting iv GC treatment. In all cases, samples were collected between 07:30 and 10:00 h. Aliquots of serum were immediately frozen at − 20 °C.
Assays
Serum carboxy-terminal telopeptide of type I collagen (CTX), amino-terminal propeptide of type I collagen (P1NP), bone alkaline phosphatase (bALP), PTH and 25OHD3 were tested with commercial kits using the following methods: a chemiluminescent enzyme immunoassay (CLIA) method, Beckman Coulter DXI 800 (Brea, CA, USA) for bALP; a CLIA method, DiaSorin Liaison XL (Stillwater, MN, USA) for 25OHD3 and PTH: and a CLIA method, Immunodiagnostic Systems (The Boldons, UK) for CTX and P1NP. The reference change values (RCV) were: 24% for bALP; 27% for CTX; and 24% for P1NP. The normal values were: 3.0-20.2 μg/l in men; 2.7-14.3 μg/l in pre-menopausal women, and 3.1-21.9 μg/l in postmenopausal women for bALP; > 75 nmol/l for 25OHD3 sufficiency; 6.5-36.8 ng/l for PTH; 115.0-748.0 pg/ml in men, 112-738 pg/ml in pre-menopausal women, and 142-1351.0 pg/ml in postmenopausal women for CTX; and 28-128 μg/l in both sexes for P1NP.
BMD and TBS
Spine and lumbar DXA were performed with the QDR Bone Densitometer Discovery (Hologic Inc., Waltham, MA) at the baseline and after 6 and 12 months. Data were recorded as BMD (g/cm 2 ) and T-scores. TBS and BMD were obtained using the fast-array imaging mode for all patients, as it is quicker to perform and involves lower radiation doses, while assuring the same performance as the array mode [14] . TBS was performed following the standard analysis procedures recommended by the manufacturer: TBS was calculated on DXA lumbar images, using iNsight Software (version 1.8.0.0; Medimaps, Merignac, France). On DXA images, morphometric vertebral fracture assessment (VFA) was done, to identify possible vertebral fractures, according to Genant et al. criteria [15] , at the beginning of end and of the study. All measurements were taken by the same operator. [16] , and later implemented [17] . The RCV is defined as "that difference between two consecutive test results that is statistically significant in a given proportion of all similar persons" [16] . The results are presented in a figure as median percentage variation.
Statistical methods
Results
Based on the World Health Organization's diagnostic parameters, i.e. the lumbar and hip BMD on baseline DXA, 5/11 patients were classified as having a normal bone mass, 4/11 as osteopenic and 2/11 as osteoporotic. Baseline clinic and densitometric characteristics of the population in study are summarized in Table 1 . The eGFR, complete blood count, liver enzymes, and glucose levels were within the normal ranges before treatment, and tests on liver autoimmunity, HBV-HCV and HBV antibodies, and quantiferon were all negative. Baseline calcium and phosphate levels were normal in all patients, and total testosterone was within the normal range in the only male patient enrolled. There were no significant differences in blood count, blood pressure, liver enzymes or glycemia at the end of the treatment vis-à-vis the baseline. Only one of the 11 patients reported an insufficient dietary intake of dairy products. Due to oral cholecalciferol loading prior to the GC treatment, 25OHD3 was within the sufficient range in all patients at the baseline (between 75 and 100 nmol/l, median value of 89.3 nmol/l). Median 25OHD levels did not change significantly during the study, although the median 25OHD peak (126.5 nmol/l) was reached in the first week of the GC treatment (Table 2) . A significant drop in CTX levels was recorded 1 month after starting the treatment (after the 3rd dose of 0.5 g methylprednisone), with median values of 197.5 ng/l and 85.9 ng/l at the baseline and at 1 month, respectively, meaning a Δ49.31% reduction vis-à-vis the baseline (p = 0.0195). CTX returned to baseline levels by the subsequent measurement, at 3 months (median 181.2 ng/l; up Δ95.84% from the previous measurement; but not statistically significant, p = 0.160). Then CTX peaked at 12 months, when it was higher (though not to a significant degree) than at the baseline (median 233.7 ng/l at 12 months, up Δ22.15% from the baseline, p = 0.278) (see Fig. 1 for the trend) .
The trends of the other bone markers were charted throughout the study period, but no significant changes emerged (Fig. 1 ). There was a modest (statistically insignificant), but persistent decrease in P1NP from baseline levels (up to 12 months after starting the treatment) as of the first dose of GC and most evident at 12 months (median 81.4 μg/l at the baseline and 52.9 μg/l at 12 months, down Δ22.12%, Fig. 1 and Table 2 ). PTH remained substantially unaltered throughout the study, although the levels at the end of the study were higher than at the baseline (median values of 18.6 ng/l at baseline and 26.4 ng/l at 12 months, up Δ33.25%, see Fig. 1 and Table 2 ). Bone alkaline phosphatase also remained much the same, with only a modest decrease after starting the treatment and a final value at 12 months slightly higher than the baseline (up to a median value of 13.47%, Fig. 1 and Table 2 ). There were no changes in lumbar, total hip or neck BMD, or lumbar TBS at 6 and 12 months (Table 2) . No vertebral fractures were identified at the morphometric VFA analysis of DXA images, at the baseline and at the end of the study.
Discussion
Although it was conducted on only a small group of patients, this is the first study (to our knowledge) to have prospectively examined the biochemical and densitometric effects on bone of high doses of GCs given in the setting of GO (Table 3) .
Bone remodeling occurs in two phases: bone resorption and bone formation. Briefly, during the former, a stage lasting 4-6 weeks, osteoclasts remove bone tissue, forming resorption cavities, and products of bone catabolization are released into the bloodstream. This is followed by a bone formation phase, in which osteoblasts fill these cavities with new bone (releasing bone formation markers), then this new bone is mineralized. The whole process of bone formation takes 4-5 months altogether [18] . CTX and P1NP are recommended as reference markers of bone resorption and bone formation, respectively [19] . CTX is a product of the degradation of type I collagen and it is specific for bone. P1NP is a post-translational derivative of type I procollagen cleavage and it derives mainly from bone [18] . Corticosteroid treatment is known to suppress bone formation and this was reflected, in our study, in a rapid (albeit moderate) reduction in P1NP levels, which remained below the basal levels even after GC had been withdrawn (Fig. 1) . The effects of GCs on bone resorption are less well characterized [20] . In previous studies, CTX dropped as a consequence of 1 week of 60 mg daily prednisone administration, but even lower doses (prednisone 10 mg daily over 1-2 weeks) reduced CTX levels by 10% [21] . In a randomized controlled trial on postmenopausal women given 5 mg of prednisone daily for 6 weeks, Ton et al. found a significant CTX suppression 4 weeks after starting the treatment. Our findings confirm the results obtained in the above-mentioned studies as regards the short-term effects of lower doses of GCs on bone [20] [21] [22] , since we recorded a Fig. 1 Effects of GC administration on biochemical parameters of bone metabolism. 25OHD3, bALP, PTH, PINP and CTX were measured on morning fasting blood samples at baseline, 1 week and 1, 3, 6 and 12 months from treatment start. The red dashed line indicates that the 6th week corresponds to a change in administered methylprednisone dose. The black dashed line indicates the 12th week, the therapy withdrawal significant CTX suppression after 4 weeks of treatment. But CTX returned to baseline levels at 3 months, even though the treatment was still underway. This behavior in serum CTX was seen in the Ton et al. trial too. This could reflect the change in dosage (after 6 weeks, patients switched from 0.5 to 0.25 g/week, or from 0.25 g/week to nothing) or some sort of adaptation of the skeleton to prednisone. That the median values were higher at 12 months (up Δ22.15%) than at the baseline would suggest a slightly higher turnover, consistent with the evidence of the reversibility of the effects of GCs on bone after withdrawing long-term GC treatment [23] . Our patients' bALP levels remained unchanged throughout the study, confirming previous reports [24, 25] . The reason for this could lie in the mechanism of action of GCs on bone (which affects bone turnover more than bone mineralization), or it may be that the bALP gene is not directly influenced by GCs [26] .
As for the effect of GCs on BMD levels, there was no difference in our patients' BMD at 6 and 12 months vis-à-vis their baseline levels. Here again, our data are consistent with a previous report from Dovio et al., who found no change in BMD after 6 months in patients with multiple sclerosis given 15 mg/kg of methylprednisone over a period of 10 days; the Authors wondered whether any effects would emerge from a longer follow-up [25] . We checked BMD at 12 months too, and there was still no difference in our sample.
Another unsolved question was whether short periods of high-dose GCs could affect the bone microarchitecture. Our patients showed no change in TBS at 6 and 12 months, indicating that the GC regimen used to treat GO does not negatively affect bone mineral content or bone micro-architecture. Finally, no vertebral fractures were identified at the morphometric VFA using DXA images. Although considering all the limitation of these technique (lower spatial resolution, non-accessibility of the upper thoracic level) [27] this is also an important data to consider, since vertebral fractures can occur without significant change in bone markers, BMD and TBS values.
This study has several limitations that need to be acknowledged. First of all, there is the small number of patients enrolled and the heterogeneity of the sample studied, including both pre-and post-menopausal women, with a wide age range, even though major influences on bone safety other than the GC treatment were ruled out. We consider this a pilot study that was able to produce some useful preliminary information for the design of larger prospective trials on the bone safety of GO treatment.
It is also of paramount importance to bear in mind that all our patients were given a load of cholecalciferol (300,000 IU) a week before starting the GC treatment. We chose to pretreat patients this way so that any baseline 25OHD3 insufficiency could not negatively influence bone turnover markers or bone imaging findings. This cholecalciferol load may have influenced their bone metabolism, however, preventing us from seeing any significant changes-in PTH, in particular [28] -although hyperparathyroidism is unlikely to play an important part in the effects of GCs on bone [29] . High doses of cholecalciferol are known to interfere with bone turnover by increasing bone resorption, but this was not the case in our sample because higher doses, starting from 600,000 IU, are needed to see this effect [28] . Our patients only showed a very modest, transient and statistically insignificant increase in CTX levels after the first week of treatment, and-judging from findings reported by Rossini et al. [28] -this might relate to the cholecalciferol load.
In conclusion, short-term, high-dose GC therapy for GO revealed only transient effects on bone turnover markers, and did not cause any significant decrease in BMD or TBS. This therapy was, therefore, harmless in terms of bone safety, in our small prospective series of patients. Further studies are needed to confirm our results of course, owing to the numerosity of our sample.
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